10 NPS Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $NPSP | NASDAQ:NPSP | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact NPS Pharmaceuticals Company Profile (NASDAQ:NPSP) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for NPS Pharmaceuticals (NASDAQ:NPSP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 4 Hold Rating(s), 10 Buy Rating(s)Consensus Rating:Buy (Score: 2.71)Consensus Price Target: $40.29 (21.42% upside) Analysts' Ratings History for NPS Pharmaceuticals (NASDAQ:NPSP) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/19/2014ZacksReiterated RatingNeutral -> Neutral$40.00View 2/19/2014Needham & CompanyBoost Price TargetBuy$28.00 -> $46.00View 2/19/2014Jefferies GroupDowngradeBuy -> Hold$38.00View 2/6/2014ZacksReiterated RatingNeutral -> Neutral$34.00View 1/20/2014TheStreetUpgradeSell -> HoldView 1/9/2014Brean CapitalBoost Price Target$36.00 -> $41.00View 1/6/2014Canaccord GenuityBoost Price TargetBuy$35.00 -> $42.00View 11/7/2013Jefferies GroupBoost Price TargetBuy$21.00 -> $28.00View 11/7/2013Canaccord GenuityBoost Price TargetBuy$25.00 -> $35.00View 11/6/2013Leerink SwannReiterated RatingOutperform$47.00View 11/6/2013Brean CapitalUpgradeHold -> Buy$36.00View 10/17/2013MLV & Co.Boost Price TargetBuy$18.00 -> $39.00View 10/9/2013Summer StreetBoost Price TargetBuy$33.00 -> $39.00View 10/3/2013Bank of AmericaInitiated CoverageBuy$46.00View 10/3/2013WedbushSet Price TargetOutperform$29.00 -> $43.00View 10/3/2013Bank of AmericaInitiated CoverageBuy$46.00View 10/2/2013OppenheimerBoost Price TargetOutperform$28.00 -> $39.00View 9/26/2013Leerink SwannBoost Price Target$47.00View 9/25/2013Janney Montgomery ScottBoost Price TargetBuy$45.00View 9/20/2013JPMorgan Chase & Co.Initiated CoverageOverweight$40.00View 9/5/2013Leerink SwannSet Price TargetOutperform$25.00 -> $35.00View 8/21/2013OppenheimerBoost Price TargetOutperform$19.00 -> $28.00View 8/13/2013BMO Capital MarketsBoost Price TargetMarket Perform$14.00 -> $19.00View 8/12/2013ZacksDowngradeOutperform -> Neutral$23.30View 8/9/2013WedbushBoost Price TargetOutperform$22.00 -> $29.00View 8/9/2013Leerink SwannBoost Price TargetOutperform$21.00 -> $25.00View 8/9/2013Jefferies GroupBoost Price TargetBuy$18.00 -> $21.00View 8/9/2013Canaccord GenuityBoost Price Target$20.00 -> $25.00View 8/9/2013Needham & CompanyBoost Price TargetBuy$20.00 -> $28.00View 7/18/2013Leerink SwannBoost Price TargetOutperform$18.00 -> $21.00View 7/12/2013ZacksUpgradeNeutral -> Outperform$18.30View 5/17/2013MLV & Co.Boost Price TargetBuy$16.00 -> $18.00View 5/14/2013TheStreetUpgradeSell -> HoldView 5/10/2013Jefferies GroupBoost Price TargetBuy$16.00 -> $18.00View 5/9/2013Needham & CompanyBoost Price TargetBuy$15.00 -> $20.00View 4/24/2013OppenheimerInitiated CoverageOutperform$18.00View 4/22/2013Jefferies GroupReiterated RatingBuy$16.00View 3/20/2013WedbushReiterated RatingOutperform$19.00 -> $22.00View 3/20/2013Jefferies GroupBoost Price TargetBuy$15.00 -> $16.00View 3/19/2013Canaccord GenuityBoost Price TargetBuy$16.00 -> $20.00View 3/19/2013Brean CapitalDowngradeBuy -> HoldView 2/22/2013Janney Montgomery ScottInitiated CoverageBuy$20.00View 1/31/2013Janney Montgomery ScottInitiated CoverageBuy$20.00View 10/17/2012Jefferies GroupBoost Price TargetBuy$13.00 -> $15.00View 10/4/2012Morgan StanleyInitiated CoverageOverweightView 10/3/2012MLV & Co.Initiated CoverageBuy$15.00View 10/3/2012MLV & Co.Initiated CoverageBuyView 9/27/2012Jefferies GroupReiterated RatingBuy$13.00View 8/14/2012Jefferies GroupReiterated RatingBuyView 8/2/2012Canaccord GenuityReiterated RatingBuyView 8/2/2012Needham & CompanyReiterated RatingBuyView 7/23/2012Leerink SwannReiterated RatingOutperformView 7/18/2012Needham & CompanyReiterated RatingBuyView 7/9/2012WedbushBoost Price Target$18.00View 6/27/2012BMO Capital MarketsReiterated RatingMarket Perform$5.00View 6/26/2012Canaccord GenuityReiterated RatingBuyView 6/26/2012Needham & CompanyReiterated RatingBuyView 6/14/2012Canaccord GenuityReiterated RatingBuyView 5/7/2012ThinkEquityInitiated CoverageBuyView 5/7/2012Canaccord GenuityInitiated CoverageBuyView 5/4/2012Needham & CompanyReiterated RatingBuyView (Data available from 3/10/2012 forward) Earnings History for NPS Pharmaceuticals (NASDAQ:NPSP)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/27/2014Q413$0.02$0.07$44.22 million$54.45 millionViewListenView 11/6/2013Q313($0.02)($0.01)$38.40 million$39.20 millionViewListenView 8/8/2013Q2 2013($0.07)($0.13)$31.62 million$36.50 millionViewListenView 5/9/2013Q1 2013($0.13)($0.09)$27.56 million$25.43 millionViewListenView 2/21/2013Q4 2012($0.09)($0.14)$28.93 million$27.10 millionViewListenView 11/9/2012Q312($0.16)($0.04)$28.18 million$27.02 millionViewN/AView 8/1/2012($0.09)$0.08ViewN/AView 5/3/2012($0.11)($0.12)ViewN/AView 2/15/2012($0.11)($0.10)ViewN/AView 11/3/2011($0.10)($0.14)ViewN/AView 8/2/2011($0.07)($0.07)ViewN/AView 5/3/2011($0.12)($0.13)ViewN/AView 2/15/2011($0.20)($0.09)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for NPS Pharmaceuticals (NASDAQ:NPSP)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for NPS Pharmaceuticals (NASDAQ:NPSP)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/13/2014Georges GemayelDirectorSell6,188$37.70$233,287.60View 1/8/2014Luke BesharCFOSell31,588$35.01$1,105,895.88View 12/26/2013Luke BesharCFOSell37,874$30.02$1,136,977.48View 12/23/2013James GroningerDirectorSell3,000$29.50$88,500.00View 12/18/2013Ed StratemeierSVPSell205,432$25.13$5,162,506.16View 9/20/2013Luke BesharCFOSell50,000$30.26$1,513,000.00View 9/16/2013Joseph RogusVPSell25,312$28.11$711,520.32View 9/16/2013Luke BesharCFOSell50,000$27.89$1,394,500.00View 8/30/2013Roger GarceauCMOSell110,000$25.18$2,769,800.00View 8/20/2013James GroningerDirectorSell16,900$23.21$392,249.00View 5/9/2013Luke M BesharCFOSell45,150$14.18$640,227.00View 11/15/2012Glenn R MelroseSVPBuy11,000$9.09$99,990.00View 10/3/2012Roger GarceauCMOSell140,625$9.51$1,337,343.75View (Data available from 1/1/2013 forward) About NPS Pharmaceuticals NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH). Headlines: (2/28) NPS Pharmaceuticals Joins Participants from around the World in Observing Rare Disease Day (2/26) NPS Pharmaceuticals to Present at Barclays Global Healthcare Conference (2/18) NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014 (2/19) NPS Pharma Swings to Earnings on Strong Revenues (3/5) Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS ... (2/26) Press Release (2/19) NPS Pharma Swings to Earnings on Strong Revenues - Analyst Blog (2/18) NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013 Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: NPSP CUSIP: 62936P10 Key Metrics: Previous Close: $32.5450 Day Moving Average: $36.0121200 Day Moving Average: $30.2602 P/E Ratio: N/AP/E Growth: 1.45Market Cap: $3.411BCurrent Quarter EPS Consensus Estimate: $0.25 EPS Additional Links: View NPSP on Google FinanceView NPSP on Yahoo FinanceView NPSP's Company Profile on ReutersSearch for NPS Pharmaceuticals, Inc. on Google NPS Pharmaceuticals (NASDAQ:NPSP) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.